<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077621</url>
  </required_header>
  <id_info>
    <org_study_id>PH-CP020</org_study_id>
    <nct_id>NCT02077621</nct_id>
  </id_info>
  <brief_title>Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer</brief_title>
  <official_title>The Phase II Clinical Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PhytoHealth Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PhytoHealth Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PG2 has been approved in Taiwan to treat cancer-related fatigue for advanced cancer patients.&#xD;
      The primary objective of this study is to evaluate the efficacy of PG2 on fatigue relief in&#xD;
      patients undergoing palliative abdominal surgery for cancer. The secondary endpoints,&#xD;
      including the length of hospital stay, postoperative complications, HRQL, inflammatory&#xD;
      biomarkers, the duration of antibiotic therapy, mortality during the hospital stay, weight&#xD;
      loss and body composition, will be evaluated among these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a double-blind, randomized, and placebo-controlled study. At least 40 evaluable&#xD;
      patients who are scheduled for palliative abdominal surgery for cancer will be randomly&#xD;
      assigned to the control or treatment group. Each group will have at least 20 patients and be&#xD;
      treated as follows: 1) control group: patients will accept placebo 1 dose a day (POD-1)&#xD;
      before surgery and 1 dose a day for 3 days after surgery (POD+0 to POD+2); 2) treatment&#xD;
      group: patients will accept PG2 1 dose a day (POD-1) before surgery and 1 dose a day for 3&#xD;
      days after surgery (POD+0 to POD+2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study reevaluation&#xD;
  </why_stopped>
  <start_date type="Anticipated">February 2014</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline fatigue status</measure>
    <time_frame>a day before surgery and day 1,2,7,28,56,84 after surgery</time_frame>
    <description>qustionnaires</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>13 weeks</time_frame>
    <description>patients were observed for surgical and nonsurgical complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQL)</measure>
    <time_frame>a day before surgery and for day 7,28,56,84 after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biomarkers: Serum IFN-r, IL-1b, IL-4, IL-6, IL-10 and TNF-a</measure>
    <time_frame>Before operation and on day 1, and day 7 after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of antibiotic therapy</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality during the hospital stay</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>13 weeks</time_frame>
    <description>patients will be measured during follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>a day before surgery and for day 28 after surgery</time_frame>
    <description>such as protein, mineral, body fat mass</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cancer</condition>
  <condition>Surgery</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>PG2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Group:&#xD;
PG2 (500 mg in 500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group:&#xD;
Placebo (500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PG2</intervention_name>
    <description>Powder for Injection, 500 mg PG2/500 ml normal saline</description>
    <arm_group_label>PG2</arm_group_label>
    <other_name>PG2 injection 500mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500 mL normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have cancer and are scheduled for palliative abdominal surgery for cancer&#xD;
&#xD;
          -  Age &gt; 20 years older&#xD;
&#xD;
          -  Patients who signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients, at screening, has levels greater than 2.5 times the upper limit of normal&#xD;
             liver function of alanine aminotransferase or aspartate aminotransferase.&#xD;
&#xD;
          -  Patients has a severe renal impairment (defined as serum creatinine greater than 2&#xD;
             times the upper limit of normal or BUN greater than 2.5 times the upper limit of&#xD;
             normal for range); or the subject is on dialysis.&#xD;
&#xD;
          -  Patients have ongoing infection, respiratory tract dysfunction, cardiac dysfunction or&#xD;
             immune disorder that, in the opinion of the investigator, may interfere with conduct&#xD;
             of the study.&#xD;
&#xD;
          -  Patients who are not suitable for undergoing surgery (e.g. congenital hemostatic&#xD;
             disorders) by the investigator's judgment.&#xD;
&#xD;
          -  Patients have enrolled or have not yet completed other investigational drug trials&#xD;
             within 1 month before screening.&#xD;
&#xD;
          -  Female patients are pregnant or breast-feeding.&#xD;
&#xD;
          -  Patients who require preoperative nutritional support&#xD;
&#xD;
          -  Patients with serious comorbidities (American Society of Anesthesiologists Risk Class&#xD;
             of 4 or 5).&#xD;
&#xD;
          -  Patients who is unwilling or unable to answer the quality of life questionnaires i.e.&#xD;
             the BFI-T and EORTC QLQ-C30.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Ming Wu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer-related fatigue</keyword>
  <keyword>Palliative Abdominal Surgery</keyword>
  <keyword>HRQL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

